...
首页> 外文期刊>Heart failure clinics >Editorial: Do biomarkers deserve high marks?
【24h】

Editorial: Do biomarkers deserve high marks?

机译:社论:生物标记物值得高分吗?

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

It seems that the moment of truth for any blood test is if the results can answer the critical questions we all struggle with: What's wrong with the patient? How severe is the difficulty? Tell me what I, as a clinician, should do next? Indeed, biomarkers typically have four main clinical uses:1 (1) diagnosis, (2) risk stratification, (3) guidance in the selection or titration of therapy in patients with known clinical features of disease,2 and (4) screening for preclinical disease.3 So is there a "CBC" or "PSA" for heart failure (HF)? The development of commercially available point-of-service assays for biomarkers, particularly troponins and B-type natriuretic peptide and its inactive N-terminal fragments, has led to a dramatic increase in the number of studies evaluating the potential clinical use of measurement of these biomarkers for all four of these clinical uses and particularly for HF. Biomarkers, along with other diagnostic modalities, may also be used to elucidate pathophysiologic processes, but they are not without limitations, since clinical features are a result of deviations in the dynamic equilibrium between risk factors, precipitating factors, and the body's ability to defend, repair, compensate, and respond to these factors.
机译:似乎任何血液测试的关键时刻都是结果是否能够回答我们大家都在努力解决的关键问题:患者怎么了?困难有多严重?告诉我我作为临床医生接下来应该做什么?实际上,生物标记物通常具有四个主要临床用途:1(1)诊断,(2)风险分层,(3)在已知疾病的临床特征的患者中选择或滴定治疗的指导,2和(4)临床前筛查疾病。3那么,是否存在用于心力衰竭(HF)的“ CBC”或“ PSA”?生物标志物,尤其是肌钙蛋白和B型利钠肽及其无活性的N端片段的生物标志物的商业化服务点测定方法的发展,导致评估这些方法的潜在临床应用的研究数量急剧增加。所有这四个临床用途的生物标志物,尤其是HF。生物标志物以及其他诊断方式也可用于阐明病理生理过程,但它们并非没有局限性,因为临床特征是危险因素,促发因素与人体防御能力之间动态平衡偏差的结果。维修,补偿并应对这些因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号